A practical reference on peptide analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-26 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
=== Foreign policy === Talarico supports a two-state solution to the Israeli–Palestinian conflict. He has condemned what he called Israel's "atrocities in Palestine" and "war crimes", and has criticized its role in the Gaza Strip famine. He opposes offensive U.S. aid to Israel. He supports banning the sale of offensive weapons to Israel. Talarico is a critic of the pro-Israel lobby group AIPAC. In 2025, he criticized Democrats for supporting the Gaza war during the 2024 presidential election. He called the war "the moral test of our time". Talarico has criticized the 2026 Iran war. After the initial strikes on February 28, he wrote, "No more forever wars" on Twitter. In an interview on The Briefing with Jen Psaki, Talarico said the U.S. could prevent Iran from obtaining nuclear weapons without "bombing innocent schoolchildren", referring to the 2026 Minab school attack. He also called for "immediate negotiations" to end the war.
In the cobalamins, cobalt normally exists in the trivalent state, Co(III). However, under reducing conditions, the cobalt center is reduced to Co(II) or even Co(I), which are usually denoted as B12r and B12s, for reduced and super reduced respectively. B12r and B12s can be prepared from cyanocobalamin by controlled potential reduction, or chemical reduction using sodium borohydride in alkaline solution, zinc in acetic acid, or by the action of thiols. Both B12r and B12s are stable indefinitely under oxygen-free conditions. B12r appears orange-brown in solution, while B12s appears bluish-green under natural daylight, and purple under artificial light. B12s is one of the most nucleophilic species known in aqueous solution. This property allows the convenient preparation of cobalamin analogs with different substituents, via nucleophilic attack on alkyl halides and vinyl halides. For example, cyanocobalamin can be converted to its analog cobalamins via reduction to B12s, followed by the addition of the corresponding alkyl halides, acyl halides, alkene or alkyne. Steric hindrance is the major limiting factor in the synthesis of the B12 coenzyme analogs. For example, no reaction occurs between neopentyl chloride and B12s, whereas the secondary alkyl halide analogs are too unstable to be isolated. This effect may be due to the strong coordination between benzimidazole and the central cobalt atom, pulling it down into the plane of the corrin ring. The trans effect determines the polarizability of the Co–C bond so formed.
== Mating == Researchers examined whether female beetles preferred males infected by the tapeworm Hymenolepis diminuta as mates, or noninfected males. Virgin females were found to spend more time near — and to copulate more often with — noninfected males in the experiment. Mating behavior was also found to be influenced by the mass of the male beetle. A larger male was preferred and mated with first compared to a smaller male mate. Overall, female beetles showed mating preferences for noninfected males who were larger in size. One explanation provided by researchers for this finding is that larger, noninfected males may allow females to gain genetic or material benefits.
In situ technology of phytoremediation could also be utilized, even though perchlorate phytoremediation mechanism is not fully founded yet. Bioremediation using perchlorate-reducing bacteria, which reduce perchlorate ions to harmless chloride, has also been proposed.
Complementary protein combinations make for delicious recipes – they are combinations that formed the basis of the world's traditional cuisines. We use them naturally in our cooking without even being aware of it. The three most common complementary protein combinations are: Grains (rice, corn, wheat, barley, etc.) + legumes (peas, beans, lentils) Grains and milk products Seeds (Sesame or sunflower) +legumes In 1975, both Vogue and American Journal of Nursing carried articles describing the principles and practice of protein combining. For a time, The American National Research Council and the American Dietetic Association (ADA) cautioned vegetarians to be sure to combine their proteins. Protein combining reached the pages of a general chemistry textbook in 1982:
Sources: en.wikipedia.org
==== Riots ==== Heseltine became the troubleshooter to deal with the explosion of violence in Britain's inner cities in the aftermath of the Brixton and Toxteth riots of 1981. Unemployment had reached 20% in Liverpool as a whole, but 60% among young black residents in Toxteth. Tear gas had had to be used, and the Cabinet contemplated deploying the Army. A few weeks before the riots, a Cabinet thinktank had proposed that the area be left to go into "managed decline". Thatcher visited Merseyside and it was decided that a minister should go for a longer visit. Heseltine was already chairman of the Merseyside Partnership, set up by his predecessor Peter Shore, to channel government money into Liverpool (six other partnerships existed). Heseltine visited Liverpool accompanied by a dozen or so officials from different ministries. Timothy Raison, a junior Home Office minister, went ostensibly to check on race matters but actually to ensure that Heseltine did not interfere in police matters. Heseltine visited council estates, often accompanied by gangs of grinning children trying to be noticed on television, and his flamboyance as a self-made man went down surprisingly well in a City famous for turning out flamboyant figures in the entertainment industry. He talked to black community leaders, who complained about police bias and brutality, and he later had an awkward private meeting with the Chief constable Kenneth Oxford about the matter.
== Kinase assays and profiling == Drug developments for kinase inhibitors are started from kinase assays Archived 2014-11-26 at the Wayback Machine, the lead compounds are usually profiled for specificity before moving into further tests. Many profiling services are available from fluorescent-based assays to radioisotope based detections, and competition binding assays.
The main advantages with respect to solvent gradient batch chromatography are high yields also for difficult separations, less solvent consumption, higher productivity, usage of countercurrent solid movement, which increases the separation efficiency. The process is continuous. Once a steady state is reached, it delivers continuously purified product in constant quality and quantity. Automatic cleaning in place is integrated. A pure empirical design of the operating conditions from a single solvent gradient batch chromatogram is possible.
=== 1998 === 1 January The King of Chaos, an Equinox Special which was a fictional documentary or docudrama, set 15 years in the future with Danny Webb and Christine Kavanagh, followed by the documentary Storm Over 4, which featured Channel 4's most controversial programmes, including January 1995's Beyond Love; the documentary was one of three nominees for the Originality award in the 1999 British Academy Television Awards; the mock-documentary was fictionally presented by Bella Enahoro, daughter of Nigerian Anthony Enahoro; a body is found in the Thames, missing for two days, filmed near the South Quay Footbridge, built in 1997, a few months before the production was filmed in late 1997; Everett Barnes (Burt Caesar), chief of security of Keller Corp; Robert Sinclair, chief of Keller Corp; Keller gives a speech on 18 December 2011 at the Turing Seminar; reporter Helen Parker (Christine Kavanagh); Superintendent Andrea Walker (Janet Amsden); Richard Steiner, chief of Eagle Television, obviously resemblant of Rupert Murdoch; Keller had Bulgarian heritage; the non-fictional Prof Peter Cochrane, Head of Research at BT, but he talked about a fictional story; Victor Bunin (Olegar Fedoro); Jean Tate (Margaret Enefer, now a TV producer), fictional Channel 4 reporter; non-fictional American Rob Glaser, chief of RealNetworks; David Britten (Ben Aris), fictional Director-General of the BBC, outside the Queen Elizabeth II Centre; in 2002, 40% of subscription TV channels would close; fictional MP Jean Fransley (Su Elliott).
=== Cancer treatment === Pardaxin inhibits proliferation and induces apoptosis of human cancer cell lines. Its 33-amino acid structure contains many cationic and amphipathic amino acids. This makes it easier for it to interact with anionic membranes, such as those in tumor cells, which are inherently more acidic because of the acidic environment created by more glycolysis. Pardaxin initiates caspase-dependent and caspase-independent apoptosis in human cervical carcinoma cells. Pardaxin triggers reactive oxygen species (ROS). ROS production disrupts protein folding and induces the unfolded protein response (UPR). This causes stress on the endoplasmic reticulum, which releases calcium. This leads to an increase in mitochondrial calcium, dropping its membrane potential. The pore permeability changes, and Cytochrome c (Cyt c) is released. Cyt c activates the caspase chain that leads to apoptosis. ROS also activates the JNK pathway. JNK is phosphorylated, which leads to the phosphorylation of AP-1 (transcription factor consisting of cFOS and Cjun). This results in the activation of caspases as well. ROS also causes a caspase independent pathway that results in apoptosis. When the mitochondrial membrane potential changes, apoptosis-inducing factors (AIFs) are also released. These trigger apoptosis when they enter the nucleus, not needing to involve caspases.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.